argenx Financial Statements
NASDAQ: ARGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
825.03+6.40 (+0.78%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 825.03 0.00%
argenx revenue and earnings
Net income was $1.29 billion (+55.1% year over year). Diluted earnings per share came in at $19.57, up from $12.78.
Summary generated from market data by MetaCap's automated system. Methodology
argenx income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 35.53M | 10.03M | 497.28M | 41.24M | 78.46M | 21.48M |
| Revenue growth (YoY) | — | — | +254.41% | -97.98% | +1105.72% | -47.44% | +265.25% | — |
| Cost of Revenue | 450.67M | 227.29M | 117.83M | 29.43M | — | — | — | — |
| Gross Profit | — | — | -82.30M | -19.41M | — | — | — | — |
| Operating Expenses | 3.19B | 2.27B | 1.69B | 1.17B | 888.16M | 542.53M | 292.92M | — |
| Research & Development | 1.36B | 983.42M | 859.49M | 663.37M | 580.52M | 370.88M | 220.77M | 83.61M |
| Selling, General & Admin | 1.37B | 1.06B | 711.90M | 472.13M | — | — | — | — |
| Operating Income | 1.05B | -21.65M | -425.05M | -720.34M | -348.75M | -477.62M | -198.89M | -81.85M |
| Interest Expense | 4.08M | 2.46M | 906.00K | 3.91M | 4.58M | 7.96M | — | — |
| Pretax Income | 1.28B | 85.18M | -304.50M | -729.31M | -399.74M | -605.35M | -175.92M | — |
| Income Tax | -13.43M | -747.86M | -9.44M | -19.72M | 8.52M | 3.10M | 5.29M | — |
| Net Income | 1.29B | 833.04M | -295.05M | -709.59M | -408.26M | -608.46M | -181.21M | -66.64M |
| Net Income growth (YoY) | +55.10% | — | — | — | — | — | — | — |
| EPS (Basic) | 21.08 | 13.92 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | — |
| EPS (Diluted) | 19.57 | 12.78 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | — |
| Shares Outstanding (Basic) | 61.30M | 59.86M | 57.17M | 54.38M | 51.08M | 45.41M | 38.62M | 33.42M |
| Shares Outstanding (Diluted) | 66.03M | 65.18M | 57.17M | 54.38M | — | — | — | — |
| Gross Margin | — | — | -231.62% | -193.55% | — | — | — | — |
| Operating Margin | — | — | -1196.21% | -7184.73% | -70.13% | -1158.06% | -253.49% | -381.01% |
| Net Margin | — | — | -830.36% | -7077.54% | -82.10% | -1475.29% | -230.95% | -310.22% |
This table shows 8 annual periods of argenx's income statement, from FY 2025 back to FY 2018, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ARGX's reporting calendar. What is a income statement?